Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
About Liip Hallo from St. Gallen, Zurich, Basel and Bern, and salut from Fribourg and Lausanne: we are Liip, a Swiss digital agency with a strong mindset. Around 200 experts in strategy, creation and web/app development working